ea0070aep327 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020
Jiménez Sara
, Pla Begoña
, M Ramos-Leví Ana
, Carraro Raffaele
, Lahera Marcos
, Hernando Iñigo
, Alfonso Arranz J
, Marazuela Mónica
Background: Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1-RA) whose role as a second-line treatment for patients with type 2 diabetes (T2D) has significantly increased. It has demonstrated cardiovascular safety and superiority in terms of glycaemic control and weight loss, compared to other GLP-1-RAs. The most common side effects are mild gastrointestinal, but it may also cause renal failure secondary to dehydration and an increased risk of diabetic retinopa...